Hajri A, Aprahamian M, Damgé C
INSERM Unit 61, Digestive Cell Biology and Physiopathology, Strasbourg, France.
Digestion. 1989;43(1-2):66-72. doi: 10.1159/000199863.
The effect of a peripheral cholecystokinin (CCK)-receptor antagonist, CR 1409, on pancreatic growth has been studied in the rat. 1.8 nmol/kg CCK-8 or caerulein and 3.6 nmol/kg bombesin or gastrin-releasing peptide (GRP) administered subcutaneously 3 times daily for 4 successive days increased pancreatic weight and its content in protein, enzymes and RNA but not in DNA, suggesting cellular hypertrophy. CR 1409 (10 mg/kg) administered intragastrically 30 min prior to peptides prevented pancreatic growth due to CCK-8 or caerulein but not that induced by bombesin and GRP. It is concluded that bombesin and GRP act on the exocrine pancreas directly rather than through the release of CCK.
已在大鼠中研究了外周胆囊收缩素（CCK）受体拮抗剂CR 1409对胰腺生长的影响。连续4天每天皮下注射3次1.8 nmol/kg CCK-8或蛙皮素以及3.6 nmol/kg蛙皮素或胃泌素释放肽（GRP），可增加胰腺重量及其蛋白质、酶和RNA含量，但不增加DNA含量，提示细胞肥大。在给予肽类药物前30分钟胃内给予CR 1409（10 mg/kg）可阻止CCK-8或蛙皮素引起的胰腺生长，但不能阻止蛙皮素和GRP诱导的胰腺生长。结论是，蛙皮素和GRP直接作用于胰腺外分泌部，而非通过释放CCK起作用。
